secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001493152-24-006722
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharma Q3 revenue up 68% to $15.5M; operating profit up 80% to $3.5M
--------------------------------------------------------------------------

- Revenue $15.5M for Q3 FY2024 ended Dec 31, 2023, +68% YoY from $9.2M.
- Operating profit $3.5M, +80% YoY from $1.9M.
- Growth attributable to sales of Elite Laboratories label products launched during FY2024.
- Company to hold conference call Feb 15, 2024 at 11:30 AM EST.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224006722/0001493152-24-006722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224006722/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-006722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer